Exhibit 10.11

 

OPTION CANCELLATION AND RELEASE AGREEMENT

 

This OPTION CANCELLATION AND RELEASE AGREEMENT (this “Agreement”) is entered into by and between Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Joshua Hexter (the “Participant”), effective as of September 24, 2026 (the “Effective Date”).

 

WHEREAS, the Company, for the benefit of its employees, directors, and consultants sponsors the Oramed Pharmaceuticals Inc. Amended and Restated 2019 Stock Incentive Plan (the “Plan”);

 

WHEREAS, pursuant to the stock option agreements listed on Schedule 1 hereto (collectively, the “Option Agreement”), the Company granted to the Participant, pursuant to the Plan, options to purchase an aggregate of 136,000 shares of the Company’s common stock (“Common Stock”), with the exercise prices per share of Common Stock set forth on Schedule 1 hereto (collectively, the “Option”); and

 

WHEREAS, effective as of the Effective Date and in exchange for the Restricted Stock Award (defined below), the Company and the Participant desire to cancel the entire Option as it relates to all 136,000 shares of Common Stock, so that on and after the Effective Date, the entire Option and the Option Agreement shall be cancelled and of no further force or effect.

 

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the sufficiency of which are hereby acknowledged, the parties to this Agreement agree as follows:

 

CANCELLATION OF OPTION

 

1.1 Cancellation of Option. In exchange for the consideration described in Section 1.2 below, the Participant hereby agrees that the Option Agreement and the Option granted thereunder shall be cancelled, terminated, and of no further force or effect, effective as of the Effective Date, and neither the Company nor the Participant shall have any further rights or obligations with respect to the Option, the Option Agreement, or with respect to any Common Stock of the Company that could have been purchased upon exercise of the Option under the Option Agreement.

 

1.2 Restricted Stock Award. In exchange for the Participant’s agreement to cancel the Option, the Option Agreement, and any other rights, obligations, or liabilities of the Company thereunder, and the release of claims set forth in Section 1.3 below, the Company hereby agrees to grant the Participant 75,455 shares of fully vested restricted Common Stock (the “Restricted Stock Award”), subject to the terms and conditions of the Plan and a Restricted Stock Award Agreement, in substantially the same form as attached hereto as Exhibit A (the “Award Agreement”).

 

1.3 Release.

 

(a) Effective as of the Effective Date, the Participant, for the Participant and the Participant’s successors and assigns forever, does hereby unconditionally and irrevocably compromise, settle, remise, acquit, and fully and forever release and discharge the Company and its respective successors, assigns, parents, divisions, subsidiaries, and affiliates, and its present and former officers, directors, employees, and agents (collectively, the “Released Parties”) from any and all claims, counterclaims, set-offs, debts, demands, choses in action, obligations, remedies, suits, damages, and liabilities in connection with any rights to acquire securities of the Company pursuant to the Option or the Option Agreement, and the Common Stock of the Company issuable thereunder (collectively, the “Releaser’s Claims”), whether now known or unknown, suspected or claimed, whether arising under common law, in equity, or under statute, which the Participant or the Participant’s successors or assigns ever had, now have, or in the future may claim to have against the Released Parties and which may have arisen at any time on or prior to the date hereof; provided, however, that this Section 1.3(a) shall not apply to any of the obligations or liabilities of the Released Parties arising under or in connection with this Agreement.

 

 

 

 

(b) The Participant covenants and agrees never to commence, voluntarily aid in any way, prosecute, or cause to be commenced or prosecuted against the Released Parties any action or other proceeding based on any of the released Releaser’s Claims which may have arisen at any time on or prior to the date hereof.

 

1.4 Further Assurances. Each party to this Agreement agrees that it will perform all such further acts and execute and deliver all such further documents as may be reasonably required in connection with the consummation of the transactions contemplated hereby in accordance with the terms of this Agreement.

 

1.5 Representations and Warranties. The Participant hereby represents and warrants to the Company that: (a) there are no restrictions on the cancellation of the Option; (b) the Participant has full power and authority to enter into and perform this Agreement and to carry out the transactions contemplated hereby; and (c) this Agreement constitutes the legal, valid, and binding obligation of the Participant, enforceable against the Participant in accordance with its terms. The Participant has read and understood this Agreement and is entering into this Agreement voluntarily. The Participant agrees that this Agreement provides good and valuable consideration for the Participant’s agreements contained herein.

 

MISCELLANEOUS

 

2.1 Headings. The headings that are used in this Agreement are used for reference and convenience purposes only and do not constitute substantive matters to be considered in construing the terms and provisions of this Agreement.

 

2.2 Parties Bound. The terms, provisions, representations, warranties, covenants, and agreements that are contained in this Agreement shall apply to, be binding upon, and inure to the benefit of the parties to this Agreement and their respective heirs, executors, administrators, legal representatives, and permitted successors and assigns.

 

2.3 Execution. This Agreement may be executed in two or more counterparts (including facsimile or portable document (“.pdf”) counterparts), all of which taken together shall constitute one instrument. The exchange of copies of this Agreement and of signature pages by facsimile or .pdf transmission shall constitute effective execution and delivery of this Agreement as to the parties and may be used in lieu of the original Agreement for all purposes. Signatures of the parties transmitted by facsimile or .pdf shall be deemed to be their original signatures for any purpose whatsoever.

 

2.4 Entire Agreement. This Agreement, together with the Award Agreement, contains the entire understanding of the parties to this Agreement with respect to the subject matter contained in this Agreement and supersedes all prior agreements and understandings among the parties with respect to such subject matter, including, without limitation, the Option Agreement.

 

2.5 Law Governing. This Agreement shall be governed by and construed in accordance with the substantive laws of the State of Delaware, without regard to its principles of conflict of laws.

 

2.6 Notice. Any notice required by the terms of this Agreement shall be given in writing and shall be deemed effective upon personal delivery or upon deposit with the United States Postal Service, by registered or certified mail, with postage and fees prepaid. Notice shall be addressed to the Company at its principal executive office and to the Participant at the address that he or she most recently provided to the Company.

 

[Remainder of page intentionally left blank.

Signature Page to Follow.]

 

2

 

 

IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer, and the Participant, to evidence his or her consent and approval of all the terms hereof, has duly executed this Agreement as of the date first written above.

 

  THE COMPANY:
   
  ORAMED PHARMACEUTICALS INC.
   
  By: /s/ Nadav Kidron
  Name:  Nadav Kidron
  Title: Chief Executive Officer and President
   
  THE PARTICIPANT:
   
  /s/ Joshua Hexter
  Joshua Hexter

 

Signature Page to

Option Cancellation and Release Agreement

 

3

 

 

SCHEDULE 1

 

OPTIONS CANCELLED

 

Grant date  Exercise price
($)
   Expiration date  Plan  Options
cancelled
 
September 11, 2019   3.69   September 11, 2029  2019 Plan   50,000 
February 3, 2021   10.40   February 3, 2031  2019 Plan   50,000 
January 3, 2022   13.89   January 3, 2032  2019 Plan   36,000 
Total              136,000 

 

 

Exhibit A

 

 

 

 

EXHIBIT A

 

Restricted Stock Award Agreement

 

 

 

 

 

 

 

Exhibit A